Household & Personal Products

Colgate‑Palmolive’s Q1 results show international growth, margin gains and strategic pricing, while managing commodity risks to support future shareholder value.

Unilever’s Q1 beats expectations with 4% volume growth, higher margins, €1.5bn share‑repurchase and a €750m cost‑cut—fueling a strong, margin‑focused strategy.

Estée Lauder Q3 2024: earnings dip but core EPS climbs, driven by 111SKIN partnership and robust skin‑care sales—insights on growth, risks, and the future of premium beauty.

Clorox Q3 2026 results: flat net sales, modest margin pressure from costs, but EPS up thanks to cost cuts and the GOJO acquisition, while strengthening Purell and supply‑chain initiatives.

Unilever’s Q1 beats estimates with volume‑led growth, yet currency and input risks loom; its cost‑efficiency and emerging‑market strategy hint at long‑term upside.

Colgate‑Palmolive’s Q4 2026 outlook shows modest EPS growth, strong pricing power and commodity‑cost gains, while tackling regulatory shifts and e‑commerce disruption.

Explore Kenvue’s $0.2075 quarterly dividend—its earnings strength, growth outlook, and how it fits amid regulatory and competitive pressures in consumer‑health.

Church & Dwight’s 501st dividend shows steady cash flow and disciplined policy, giving investors confidence amid a consumer‑staples market shifting toward clean‑label, e‑commerce and global growth opportunities.

Kimberly‑Clark’s 2026 outlook: modest growth, 30‑31% margin, debt‑to‑EBITDA 3.1x, and a pending Kenvue deal facing US, EU, and India antitrust reviews—learn the key risks, regulatory hurdles, and opportunities for investors.

Procter & Gamble faces a BASF battery‑tech lawsuit and rising input‑costs—explore the legal, financial, and competitive impacts on its margins and investor outlook.